Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Georgetown University
• Collaborators: National Institute of Mental Health (NIMH); Washington D.C. Veterans Affairs Medical Center
• Treatments: Aripiprazole; Choline; Cytidine Diphosphate Choline; Galantamine; Olanzapine; Quetiapine Fumarate; Risperidone; Ziprasidone

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for schizophrenia or schizoaffective disorder

• Eligible for care within the Veterans Affairs Medical system

• Taking risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole (oral or injection)

Exclusion Criteria:

• Significant liver, kidney, lung, endocrine, active peptic ulcer, or cardiovascular disease

• Seizure disorder and/or head injury

• Substance use or abuse within 3 months of study entry

• Pregnant